Abstract
Background: Interleukin (IL)-18 is a potent pro-inflammatory cytokine and plays a central role in atherosclerotic plaque rupture and accelerates atherosclerosis. Aim: The aim of this study was to determine serum IL-18 levels in patients on peritoneal dialysis (PD) and to assess their relationship with hospitalization. Methods: Forty-three PD patients and 20 healthy individuals were enrolled in this study. We investigated the relationship of the serum concentrations of IL-18 and other well-established atherosclerotic markers, such as asymmetric dimethylarginine (ADMA). Hospitalization data from over a 18-month period were prospectively obtained on all 43 PD patients. Classic factors were entered into a Cox regression model to predict first hospitalization. Results: The serum levels of IL-18 in patients on PD were significantly higher than those of healthy individuals (228.5 ± 140.3 pg/mL vs 154.8 ± 44.7 pg/mL, P < 0.05, respectively). Furthermore, serum IL-18 levels showed a positive correlation with duration of PD, serum β2 microglobulin and serum ADMA levels. Mean serum levels of IL-18 were significantly higher among patients who had experienced at least one hospitalization than those who had not (279.9 ± 164.3 vs 158.5 ± 43.9 pg/mL, P = 0.0426). Furthermore, the relative risk for first hospitalization for each increase in IL-18 (pg/mL) levels was associated with a 1.182 (95% confidence interval, 1.012-1.364; P = 0.0071) increase in the risk for future hospitalization events. Conclusion: The present study suggests the elevated serum IL-18 levels might increase the risk for future hospitalization in patients on PD.
| Original language | English |
|---|---|
| Pages (from-to) | 576-582 |
| Number of pages | 7 |
| Journal | Nephrology |
| Volume | 10 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1 2005 |
Fingerprint
Keywords
- Asymmetric dimethylarginine
- Hospitalization
- Interleukin-18
- Peritoneal dialysis
ASJC Scopus subject areas
- Nephrology
Cite this
Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis. / Yano, A. I.; Nakao, Kazushi; Sarai, A. I.; Akagi, Shigeru; Kihara, Takashi; Morimoto, Hisanori; Nakamura, Akihiko; Hiramatsu, Makoto; Nagake, Yoshio; Makino, Hirofumi.
In: Nephrology, Vol. 10, No. 6, 01.12.2005, p. 576-582.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis
AU - Yano, A. I.
AU - Nakao, Kazushi
AU - Sarai, A. I.
AU - Akagi, Shigeru
AU - Kihara, Takashi
AU - Morimoto, Hisanori
AU - Nakamura, Akihiko
AU - Hiramatsu, Makoto
AU - Nagake, Yoshio
AU - Makino, Hirofumi
PY - 2005/12/1
Y1 - 2005/12/1
N2 - Background: Interleukin (IL)-18 is a potent pro-inflammatory cytokine and plays a central role in atherosclerotic plaque rupture and accelerates atherosclerosis. Aim: The aim of this study was to determine serum IL-18 levels in patients on peritoneal dialysis (PD) and to assess their relationship with hospitalization. Methods: Forty-three PD patients and 20 healthy individuals were enrolled in this study. We investigated the relationship of the serum concentrations of IL-18 and other well-established atherosclerotic markers, such as asymmetric dimethylarginine (ADMA). Hospitalization data from over a 18-month period were prospectively obtained on all 43 PD patients. Classic factors were entered into a Cox regression model to predict first hospitalization. Results: The serum levels of IL-18 in patients on PD were significantly higher than those of healthy individuals (228.5 ± 140.3 pg/mL vs 154.8 ± 44.7 pg/mL, P < 0.05, respectively). Furthermore, serum IL-18 levels showed a positive correlation with duration of PD, serum β2 microglobulin and serum ADMA levels. Mean serum levels of IL-18 were significantly higher among patients who had experienced at least one hospitalization than those who had not (279.9 ± 164.3 vs 158.5 ± 43.9 pg/mL, P = 0.0426). Furthermore, the relative risk for first hospitalization for each increase in IL-18 (pg/mL) levels was associated with a 1.182 (95% confidence interval, 1.012-1.364; P = 0.0071) increase in the risk for future hospitalization events. Conclusion: The present study suggests the elevated serum IL-18 levels might increase the risk for future hospitalization in patients on PD.
AB - Background: Interleukin (IL)-18 is a potent pro-inflammatory cytokine and plays a central role in atherosclerotic plaque rupture and accelerates atherosclerosis. Aim: The aim of this study was to determine serum IL-18 levels in patients on peritoneal dialysis (PD) and to assess their relationship with hospitalization. Methods: Forty-three PD patients and 20 healthy individuals were enrolled in this study. We investigated the relationship of the serum concentrations of IL-18 and other well-established atherosclerotic markers, such as asymmetric dimethylarginine (ADMA). Hospitalization data from over a 18-month period were prospectively obtained on all 43 PD patients. Classic factors were entered into a Cox regression model to predict first hospitalization. Results: The serum levels of IL-18 in patients on PD were significantly higher than those of healthy individuals (228.5 ± 140.3 pg/mL vs 154.8 ± 44.7 pg/mL, P < 0.05, respectively). Furthermore, serum IL-18 levels showed a positive correlation with duration of PD, serum β2 microglobulin and serum ADMA levels. Mean serum levels of IL-18 were significantly higher among patients who had experienced at least one hospitalization than those who had not (279.9 ± 164.3 vs 158.5 ± 43.9 pg/mL, P = 0.0426). Furthermore, the relative risk for first hospitalization for each increase in IL-18 (pg/mL) levels was associated with a 1.182 (95% confidence interval, 1.012-1.364; P = 0.0071) increase in the risk for future hospitalization events. Conclusion: The present study suggests the elevated serum IL-18 levels might increase the risk for future hospitalization in patients on PD.
KW - Asymmetric dimethylarginine
KW - Hospitalization
KW - Interleukin-18
KW - Peritoneal dialysis
UR - http://www.scopus.com/inward/record.url?scp=29144459564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29144459564&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1797.2005.00497.x
DO - 10.1111/j.1440-1797.2005.00497.x
M3 - Article
C2 - 16354240
AN - SCOPUS:29144459564
VL - 10
SP - 576
EP - 582
JO - Nephrology
JF - Nephrology
SN - 1320-5358
IS - 6
ER -